载体筛检的全球市场:现状分析、预测 (2022年～2028年)

遗传性疾病的盛行率的上升，和这些疾病对儿童的影响相关意识的高涨，成为载体筛检市场推进因素。载体筛检的市场规模，由于体外受精、冻结保存的采用持续增加，预计以约15％稳定的成长率成长。

本报告提供全球载体筛检的市场调查，市场定义和概要，市场成长的各种影响因素分析，市场规模的变化、预测，各种区分、各地区/主要国家的明细，法律制度，供需趋势，竞争环境，主要企业简介等彙整资讯。

目录

第1章 简介

第2章 调查手法、前提条件

第3章 市场概要

第4章 摘要整理

第5章 COVID-19:对载体筛检市场的影响

第6章 载体筛检市场:收益的变化、预测

第7章 市场洞察:各类型

• 扩张载体筛检
• 标的疾病载体筛检

第8章 市场洞察:各疾病

• 囊状纤维化症
• 戴-萨克斯病
• 高雪氏症
• 镰状细胞贫血
• 脊髓性肌萎缩症
• 其他

第9章 市场洞察:各技术

• DNA定序
• 聚合酵素链锁反应
• 微阵列
• 其他

第10章 市场洞察:各终端用户

• 医院
• 实验室
• 诊疗所
• 其他

第11章 市场洞察:各地区

• 北美
• 欧洲
• 亚太地区
• 其他地区

第12章 载体筛检市场:市场动态

• 推动市场要素
• 市场课题
• 影响分析

第13章 载体筛检市场:市场机会

第14章 载体筛检市场:市场趋势

第15章 需求侧、供给侧的分析

第16章 价值链分析

第17章 竞争模式

第18章 企业概要

• Myriad Genetics, Inc.
• Cepheid
• Illumina, Inc
• Thermo Fisher Scientific
• F. Hoffmann-La Roche Ltd
• Laboratory Corporation of America Holdings
• Otogenetics
• MedGenome
• Genentech, Inc
• CENTOGENE N.V.

第19章 免责声明

Carrier screening is a genetic test used to determine if a healthy person is a carrier of a recessive genetic disease. It provides life-lasting information about an individual's reproductive risk and their chances of having a child with a genetic disease. Genetic disorders are considered life-long disorders, these can be happened by mutation or by the inheritance of the defaulted genes from the family. The rising prevalence of genetic disorders and the rising awareness about the effect of these disorders on the child are the driving for the market of carrier screening. For instance, the World Health Organization estimates that 10 out of every 1000 people are affected. This means that between 70 million and 80 million people in the world are living with one of these diseases.

The Carrier Screening Market is expected to grow at a steady rate of around 15% owing to the increasing adoption of In-vitro fertilization and cryopreservation. Cryopreservation and in-vitro fertilization require the genetic screening of parents to understand the risk of the genetic disorder. For instance, as per the various research reports, each year, clinicians around the world perform more than 2.5 million IVF cycles.

Based on the type, the market has been categorized into expanded carrier screening and targeted disease carrier screening. Among them, the expanded carrier screening segment holds a dominant share of the market in 2021. The expanded carrier screening tests are the tests that cover the range of genetic disorder testing. These tests are performed to access the possibility of the highest occurring genetic diseases such as Tay-Sachs diseases. The companies are expanding their product launches in the category is an important factor responsible lucrative share of the segment in the market. For instance, in February 2020, Thermo Fisher Scientific Introduces NGS-Based Solution for Expanded Carrier Screening Research. The Ion Torrent CarrierSeq ECS Kit for the Ion GeneStudio S5 System consolidates a multi-platform approach to expanded carrier screening (ECS) into a single solution that extends the company's reproductive health research portfolio, which includes tools for prenatal, postnatal, invitro fertilization, and newborn screening analysis.

Based on the medical condition, the market has been categorized into cystic fibrosis, Tay Sachs, Gaucher disease, sickle cell disease, spinal muscular atrophy, and others. Among them, sickle cell disease held a considerable share in 2021. Sickle cell anemia is among the most common genetic disorders in which the red blood cells of the body change their shape from round to sickle cell and becomes rigid which makes them incompatible to carry enough oxygen. That results in anemia, loss of vision, weak immunity, and other conditions. The high prevalence of the disease in the weaker economies attributes to the significant share of the segment. For example, as per the World Health Organization, as high as 40 percent of people in some African countries have sickle cell trait.

Based on the technology, the market has been categorized into DNA sequencing, polymerase chain reaction, microarrays, and others. Among them, the DNA sequencing segment holds a prominent share of the market un 2021. This is mainly due to technological advancements in the technology, along with the expanding product categories and launches of products based on DNA sequencing attributes to the growth of the segment. For instance, in December 2022, Bio-Techne and Oxford Nanopore Technologies announced to codevelop sequencing assays for reproductive health and carrier screening.

Based on the end-users, the market has been categorized into hospitals, laboratories, clinics, and others. Among them, the laboratories segment held the dominant share in 2021. This is mainly due to the expertise of the laboratories in the diagnosis of various genetic disorders, increasing the patient pool in the labs for the diagnosis.

For a better understanding of the market adoption of the carrier screening industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America is anticipated hold a dominant market share in 2021. The presence of the major market players and increasing demand for the early detection of the genetic condition attributes to the dominating share of carrier screening in the region. Furthermore, increasing incidences of genetic and rare diseases are the contributing factors for the market growth in the region. For instance, according to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans.

Some of the major players operating in the market are Myriad Genetics, Inc.; Cepheid; Illumina, Inc; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Otogenetics; MedGenome; Genentech, Inc; and CENTOGENE N.V.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Carrier Screening Market
• 2.2. Research Methodology of the Carrier Screening Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CARRIER SCREENING MARKET

6 CARRIER SCREENING MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Expanded Carrier Screening
• 7.2. Targeted Disease Carrier Screening

8 MARKET INSIGHTS BY MEDICAL CONDITION

• 8.1. Cystic Fibrosis
• 8.2. Tay-Sachs
• 8.3. Gaucher Disease
• 8.4. Sickle Cell Disease
• 8.5. Spinal Muscular Atrophy
• 8.6. Other

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. DNA Sequencing
• 9.2. Polymerase Chain Reaction
• 9.3. Microarrays
• 9.4. Others

10 MARKET INSIGHTS BY END-USER

• 10.1. Hospitals
• 10.2. Laboratories
• 10.3. Clinics
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 CARRIER SCREENING MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 CARRIER SCREENING MARKET OPPORTUNITIES

14 CARRIER SCREENING MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Myriad Genetics, Inc.
• 18.2. Cepheid
• 18.3. Illumina, Inc
• 18.4. Thermo Fisher Scientific
• 18.5. F. Hoffmann-La Roche Ltd
• 18.6. Laboratory Corporation of America Holdings
• 18.7. Otogenetics
• 18.8. MedGenome
• 18.9. Genentech, Inc
• 18.10. CENTOGENE N.V.

19 DISCLAIMER